Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has a rich pipeline reserve that lays the foundation for growth, with a focus on product sales progress [1] - The company is expected to achieve a net profit of 1.423 billion yuan in 2026, corresponding to a PE ratio of 27.4 times [7] - The company is pursuing a dual strategy of "R&D + M&A" to drive growth, with a strong emphasis on new product approvals and international business integration [7] Financial Performance Summary - For 2025, the company reported revenue of 2.453 billion yuan, a decrease of 18.9% year-on-year, and a net profit of 1.291 billion yuan, down 34.1% [7] - The core product revenue saw a decline, with solution-type injection products generating 1.265 billion yuan (down 27.5%) and gel-type injection products generating 890 million yuan (down 26.8%) [7] - The company has a comprehensive gross profit margin of 92.7% for 2025, which is a decrease of 1.9 percentage points [7] Earnings Forecast - Projected revenues for the years 2024 to 2028 are as follows: 3.026 billion yuan (2024), 2.453 billion yuan (2025), 2.775 billion yuan (2026), 3.058 billion yuan (2027), and 3.116 billion yuan (2028) [6] - The expected net profit for the years 2026 to 2028 is 1.423 billion yuan (2026), 1.582 billion yuan (2027), and 1.635 billion yuan (2028) [7] - The company’s return on equity (ROE) is projected to be 17.1% in 2026, decreasing to 16.3% by 2028 [6] Product Pipeline and Strategic Initiatives - The company has a robust pipeline with 12 Class III medical device product registrations, including the recently approved botulinum toxin type A and minoxidil solution [7] - The launch of the new product "Kakola" in May 2025 aims to enhance the product portfolio in facial contouring treatments [7] - The company has made strategic acquisitions, including REGEN in South Korea, to deepen its international strategy and enhance its regenerative product matrix [7]

Summary of Conference Call Notes Industry Overview: Northeast Retail - **Mid-to-High-End Consumer Recovery**: CR (China Resources) reported a year-on-year growth of over 10% in January and February, outperforming Q4. Luxury goods continue to see growth, indicating a positive trend in consumer spending [1] - **Sector Allocation**: With the earnings release period in March-April, consumer sectors may serve as a defensive play, as overall valuations are currently at a low level [2] Medical Aesthetics - **Profit Shift to End Institutions**: Companies such as AMK, Jinbo, and Haohai Medical Beauty reported earnings misses. The acceleration of product certifications has led to a deteriorating market competition landscape and price declines [3] - **Long-term Benchmarking**: The sector is being compared to South Korean companies with gross margins of 80% and net margins of 30%. Short-term focus is on Four Rings Pharmaceutical, which is expected to release new products, while the long-term profit chain is shifting downstream to end institutions [4] Cosmetics - **Negative News Already Priced In**: The leading companies in the sector have performed well during the March-April earnings period, with companies like Juzhibio and Shangmei meeting expectations. The 38 promotional event has seen low expectations and intensified competition already factored into prices [5] - **Future Market Concentration**: The market is expected to concentrate around leading brands, with valuations for brands like Mao Ge Ping and Ruo Yu Chen at 20-25x PE, while Shangmei, Juzhibio, Pola, and Linqingxuan are around 15x PE [6] Gold and Jewelry - **Negative Beta Industry Amid Price Fluctuations**: Data from January and February exceeded expectations, but companies like CHJ and ZDF are under pressure due to high base effects. Fluctuating gold prices are impacting wedding and self-gifting demands [7] - **Long-term Focus on VAT Benefiting Brands**: Brands such as Cai Bai and Hong Kong-listed brands are expected to benefit from VAT changes [8] Individual Company Updates - **Xirui**: The annual report may present a buying opportunity, as recent declines are attributed to rising oil prices and U.S. stagflation. The annual report will disclose current orders, and multiple new aircraft models in 2026 are expected to drive demand and support performance in 2026-2027, currently trading at 11x PE [9] - **Focus Technology**: Attention is on the commercialization pace of AI products on the buyer's side. The 2025 earnings are expected to meet forecasts, with a target of over 20% cash income recovery for China Manufacturing Network in 2026. The AI business is gradually improving [10]

Industry and Company Analysis - The lithium battery industry is experiencing accelerated industrialization, with companies like Samsung SDI and Chasing releasing AI-specific all-solid-state batteries, and plans for mass production by 2027 [3][33] - CATL maintains high-speed growth in performance, indicating strong market demand and operational efficiency [3][33] - The European natural gas futures prices are rising, which may impact energy costs for battery production and overall industry dynamics [3][33] Financial Performance Insights - BOSS Zhipin reported a revenue growth rate exceeding expectations for Q4 2025, indicating a positive trend in spring recruitment [3][33] -卓越教育集团 emphasizes high dividends and shareholder returns, suggesting a competitive advantage in the Greater Bay Area [3][33] - Huazhu Group's operational turning point is validated, with expansion in market share and cyclical recovery [3][33] - Tencent is actively investing in AI, focusing on enhancing model capabilities, which may drive future growth [3][33] - Zhongan Online's diversified layout has deepened, leading to significant profit improvements [3][33] - Dongfang Caifu's performance is on an upward trend, seeking new growth spaces [3][33] - Nanjing Steel's main business profitability remains stable, although its coking business has negatively impacted overall performance [3][33] - Guokang Gold Group is progressing with the expansion of its mining capacity, indicating strong future growth potential [3][33] - Juzhi Biotechnology's short-term adjustments do not alter its long-term growth logic, with a promising pipeline in the medical beauty sector [3][33]

Group 1 - The core viewpoint is that the market is currently facing significant uncertainty due to geopolitical tensions and economic conditions, with a decisive direction expected to emerge around April [2] - The article discusses three key unresolved questions regarding the Iran conflict, U.S. Federal Reserve's focus, and China's economic situation, which are crucial for market predictions [2] - The market has seen some short-term reduction in positions, particularly in previously high-performing sectors, but overall returns have reverted to the starting line since the beginning of the year [2] Group 2 - The article identifies sectors that may maintain independent high prosperity despite geopolitical tensions and high oil prices, highlighting the importance of sectors like optical communication and energy storage [3] - It suggests that sectors with upward trends and less sensitivity to oil prices, such as energy storage and domestic AIDC chains, should be prioritized for investment [3] Group 3 - The current phase is described as potentially the most pressured stage due to the ongoing U.S.-Iran conflict, with a focus on the divergence between stable policy and absolute return strategies [4] - The article emphasizes that the mid-term variables are underestimated, particularly regarding inflation tolerance and the resilience of the U.S. and Chinese economies [4][5] Group 4 - A-shares are expected to have limited downside potential, with the market likely to experience oscillation and structural rotation as it absorbs external pressures [6] - Key sectors to watch include energy-related industries, defensive assets, and technology innovation sectors, with a focus on undervalued consumer segments [6] Group 5 - The market is anticipated to undergo a prolonged period of consolidation due to the impact of the U.S.-Iran conflict and changing expectations regarding interest rates [7] - The article highlights three investment directions: industries benefiting from high oil prices, stable cash flow defensive stocks, and certain growth sectors that may be undervalued [7] Group 6 - China's manufacturing sector is positioned for a value reassessment, with leading industries in coal chemical and power equipment showing resilience and potential for growth [8] - The article notes that China's energy system's completeness reduces vulnerability to external shocks and enhances its role in global energy supply [8] Group 7 - The narrative around the rise of physical assets remains intact, with a focus on energy security and the potential for China's manufacturing sector to serve as a stabilizing force in the global economy [9] - Investment recommendations include sectors related to energy, manufacturing, and consumer goods that are expected to benefit from structural changes in the market [9] Group 8 - The current market adjustment is attributed to concerns over economic stagnation and escalating conflict risks, with a potential for market recovery when sentiment is at its lowest [11] - Investment strategies should focus on sectors that benefit from rising oil prices and those with clear growth prospects, particularly in technology and renewable energy [11] Group 9 - The market is expected to remain under pressure from external factors, but there are positive indicators such as proactive monetary policy and strong early economic data [12] - The article suggests a dual focus on growth and cyclical sectors, with an emphasis on clean energy and resource-related investments [12] Group 10 - The outlook for the market suggests a gradual stabilization post-mid-March, with a focus on both growth and value sectors, particularly in energy and technology [13] - The article encourages investment in sectors that are likely to benefit from ongoing trends in AI and traditional industries undergoing value reassessment [13] Group 11 - The ongoing U.S.-Iran conflict and shifting interest rate expectations are impacting global markets, with a focus on stable domestic policies providing a clearer investment environment [14] - Recommended sectors include defensive strategies, energy independence, and high-growth areas such as AI and energy storage [14]

Group 1: Market Dynamics - The recent market downturn is primarily driven by a strong dollar rather than weak demand, as the US-Iran conflict has reversed the previous "weak dollar" narrative[2] - Prior to the conflict, the dollar was weak, leading to capital outflows from dollar assets, with US stocks underperforming globally[2] - Following the outbreak of the conflict, the dollar index rebounded significantly, resulting in a relative resilience of US stocks compared to other global markets[2] Group 2: Economic Structure and Energy Consumption - The US economy, with a service-oriented structure, consumes significantly less traditional energy per unit of GDP compared to other economies, which mitigates the impact of energy shocks[3] - Traditional energy consumption is higher in manufacturing sectors, particularly in East Asian economies, which face greater pressure from supply chain disruptions[3] - The current global economic landscape reflects a shift in asset performance, with a preference for sectors less reliant on traditional energy consumption[3] Group 3: Commodity Market Insights - The recent decline in commodity prices is attributed to a reallocation of dollar liquidity rather than an outright recession, with expectations of monetary policy tightening being overly pessimistic[4] - The market's current pricing of the Federal Reserve's monetary policy is extreme, with a significant discrepancy between market expectations and the Fed's own projections[4] - The decline in commodity prices, particularly in higher-value items, indicates a shift in market dynamics influenced by the strong dollar[4] Group 4: Chinese Market Opportunities - Amid rising global energy security concerns, China's advantages in coal chemical and power equipment industries are becoming more apparent[5] - China's solar energy production capacity is equivalent to 24% of the total oil exports from the Strait of Hormuz, highlighting its potential as a global energy alternative[5] - The valuation of leading Chinese manufacturing firms is at historically low levels, suggesting a potential for revaluation as domestic demand shows signs of recovery[5]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [3]. Core Insights - The company experienced a decline in revenue and net profit in 2025, primarily due to pressures in its core segments: medical aesthetics and ophthalmology [8]. - The report anticipates a recovery in performance driven by the release of high-end products in the medical aesthetics and ophthalmology sectors [8]. - The company maintains a high dividend payout ratio, distributing 90.5% of its net profit to shareholders [8]. Financial Forecasts - Revenue is projected to grow from 24.73 billion CNY in 2025 to 30.32 billion CNY by 2028, with annual growth rates of -8.3%, 5.0%, 7.6%, and 8.6% respectively [2]. - Net profit is expected to rebound significantly from 2.51 billion CNY in 2025 to 4.68 billion CNY in 2028, reflecting growth rates of -40.3%, 46.3%, 12.3%, and 13.4% [2]. - Earnings per share (EPS) is forecasted to increase from 1.09 CNY in 2025 to 2.03 CNY in 2028 [2]. Segment Performance - The medical aesthetics segment reported a revenue of 1.04 billion CNY in 2025, down 12.97% year-on-year, with hyaluronic acid products particularly affected [8]. - The ophthalmology segment generated 7.25 billion CNY in revenue, a decline of 15.50%, influenced by price adjustments from centralized procurement and fluctuating demand [8]. - High-end differentiated products in both segments are expected to drive future growth as market conditions stabilize [8].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the launch of JD's cross-border e-commerce platform Joybuy in six European countries, marking a shift to comprehensive retail operations and emphasizing a self-operated model to enhance competitive differentiation [25][27] - The report suggests focusing on high-quality companies in sectors benefiting from emotional consumption themes, including gold jewelry, offline retail, cosmetics, and medical aesthetics [7][30][31] Industry Overview - The retail and social service indices reported a decline of 4.55% and 4.00% respectively during the week of March 16-20, 2026, with the retail index down 12.57% year-to-date [6][15] - The hotel and restaurant sector showed the smallest decline this week, while it has the highest growth year-to-date at 3.19% [18][20] Company-Specific Insights - Joybuy's self-operated model is expected to create a competitive edge through quality control and service reliability, with over 60 logistics warehouses established in Europe [27][28] - The report recommends several companies based on their growth potential: - **Old Puhuang**: Expected net profit growth of 226%-233% in 2025, driven by channel expansion and brand enhancement [32][41] - **Chao Hong Ji**: Anticipated net profit growth of 125%-175% in 2025, supported by differentiated product strength and multi-channel marketing [35] - **Mao Ge Ping**: Expected revenue growth of 31.3% in H1 2025, benefiting from its position as a high-end domestic cosmetics brand [35] - **Meili Tianyuan Medical Health**: Projected net profit growth of 34% in 2025, leveraging strong market positioning in high-end beauty [35] Market Dynamics - The report emphasizes the importance of adapting to consumer trends, with a focus on emotional value and innovative product safety in cosmetics and personal care [30][31] - Companies are encouraged to explore opportunities in the evolving landscape of cross-border e-commerce, particularly those with strong brand and supply chain capabilities [27][30]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.04 [7]. Core Insights - The company is expected to achieve revenue of RMB 2.453 billion in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to the parent company of RMB 1.291 billion, down 34.05% year-on-year. This decline is attributed to the medical beauty industry entering a mature and regulated phase, leading to intensified competition and slowing growth [1][5]. - The company has a rich pipeline of products, with new approvals progressing steadily. The recent approval of a botulinum toxin product and the registration of minoxidil lotion are expected to contribute positively to future revenues [4][5]. - The company is actively expanding its product lines, particularly in the freeze-dried powder category, which has shown significant revenue growth. The introduction of new products is anticipated to create new growth points and potentially restore revenue growth in 2026 [2][5]. Summary by Sections Financial Performance - In 2025, the company reported a gross margin of 92.7%, a decrease of 1.95 percentage points year-on-year. The gross margin for solution products was 93.1%, and for gel products, it was 97.3% [3]. - The sales expense ratio increased to 15.8%, primarily due to higher personnel costs and increased expenses related to sales activities [3]. Product Sales Structure - The revenue from solution injection products was RMB 1.265 billion, down 27.48% year-on-year, accounting for 51.57% of total revenue. Gel injection products generated RMB 890 million, down 26.82%, making up 36.27% of total revenue. Freeze-dried powder injection products contributed RMB 208 million, accounting for 8.48% [2]. Pipeline and New Products - The company has made significant progress in its product pipeline, with several products entering the registration and approval stages. The approval of the botulinum toxin product is particularly noteworthy as it is the seventh compliant product of its kind approved in China [4]. Earnings Forecast and Valuation - The revenue forecast for 2026 is adjusted to RMB 2.829 billion, reflecting a growth of 15.33% year-on-year. The net profit forecast for 2026 is slightly reduced to RMB 1.422 billion, down 14.9% from previous estimates [5][11]. - The company is valued at a price-to-earnings ratio of 33 times, with a target price adjustment reflecting a premium rate [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The skincare business is expected to regain momentum in the second half of the year, while the medical aesthetics segment is building a new growth curve [1] - The company reported a revenue of 5.52 billion yuan for 2025, a slight decrease of 0.4% year-on-year, and a net profit attributable to shareholders of 1.91 billion yuan, down 7.2% year-on-year [3][4] - The first half of 2025 saw a revenue of 3.11 billion yuan, up 22.5% year-on-year, while the second half experienced a decline of 19.8% [3][4] Revenue Performance - The company's professional skincare products generated revenue of 5.50 billion yuan in 2025, with functional skincare products accounting for 4.34 billion yuan, a year-on-year increase of 0.8% [4] - The revenue from the medical dressing segment was 1.16 billion yuan, down 4.8% year-on-year [4] - The company's main brand, 可复美, generated 4.47 billion yuan in revenue, a decrease of 1.6% year-on-year, while the 可丽金 brand saw a revenue increase of 9.2% to 0.92 billion yuan [4] Product and Brand Development - In 2025, the company launched the 可复美胶原棒 2.0 and plans to introduce significant new products in 2026 [5] - The company is also focusing on expanding its product matrix with new launches in various series, which is expected to optimize revenue structure [7] Financial Metrics - The company's gross margin decreased by 1.8 percentage points to 80.3% in 2025, attributed to changes in product mix and a decline in high-margin medical dressing revenue [6] - The sales, management, and R&D expense ratios were 37.3%, 3.1%, and 1.6% respectively, with an increase in sales expense ratio due to heightened brand investment [6] Future Outlook - The company is expected to return to a growth trajectory through continuous product innovation and expansion in the medical aesthetics sector [7] - The net profit forecasts for 2026 and 2027 have been adjusted to 2.01 billion yuan and 2.37 billion yuan, respectively, reflecting a downward revision of 42% and 47% [7]

Investment Rating - The report maintains a "Positive" outlook on international cosmetics and medical beauty companies for 2025 [2]. Core Insights - The global beauty market is expected to grow at a slow pace of 3.5% in 2025, down from 4.5% in 2024 and 8% in 2023, indicating a continued decline in demand [3][13]. - In the Chinese market, the cosmetics retail sales growth is projected to improve to 5.1% in 2025, recovering from negative growth in 2024, with international brands seeing a resurgence [3][18]. - Major international companies like L'Oréal and Procter & Gamble are expected to show stable growth, while others may face revenue pressures [3][14]. Summary by Sections 1. Global Beauty Market Performance - The global beauty market is stabilizing after a period of decline, with a growth rate of 3.5% in 2025 [3][13]. - Demand-side weaknesses continue to challenge international groups, necessitating strategic adjustments [14]. 2. L'Oréal's Performance - L'Oréal's revenue growth for 2025 is projected at 1.3%, with a slight improvement in Q4 compared to Q3 [3][24]. - The company is focusing on brand acquisitions and enhancing its online presence in China to adapt to market changes [21][24]. 3. Estée Lauder's Strategy - Estée Lauder's overall revenue for 2025 is expected to be $14.67 billion, reflecting a 3.3% decline year-over-year, but Q4 shows a positive growth trend [3][47]. - The company is implementing strategic reforms to address previous challenges, particularly in the Chinese market [44][47]. 4. Shiseido's Challenges - Shiseido's revenue is forecasted to decline by 2.1% in 2025, with operating profit turning negative [3][17]. - The company is experiencing fluctuations in performance, particularly in the Chinese market, which is expected to remain volatile [3][18]. 5. Investment Recommendations - The report recommends focusing on companies with strong channel and brand matrices, such as Mao Ge Ping and Shangmei, as well as those with improving performance like Proya and Marubi [4]. - In the medical beauty sector, companies with strong R&D capabilities and product pipelines, such as Aimeike and Langzi, are highlighted as potential investment opportunities [4].